Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC

Molecular therapies for HCC: Looking outside the box

(2020) Sandrine Faivre et al.   JOURNAL OF HEPATOLOGY

Siah2 control of T-regulatory cells limits anti-tumor immunity

(2020) Marzia Scortegagna et al.   Nature Communications

Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice

(2020) David Kung-Chun Chiu et al.   GASTROENTEROLOGY

Intratumoral γδ T‐cell infiltrates, CCL4/5 protein expression and survival in patients with hepatocellular carcinoma

(2020) Na Zhao et al.   HEPATOLOGY

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenvatinib and pembrolizumab in advanced gastric cancer

(2020) Stefano Cascinu   LANCET ONCOLOGY

IL ‐10 producing type 2 innate lymphoid cells prolong islet allograft survival

(2020) Qingsong Huang et al.   EMBO Molecular Medicine

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

(2020) Shogo Kumagai et al.   NATURE IMMUNOLOGY

Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis

(2020) James C. Lee et al.   Science Immunology

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

(2019) Yu Kato et al.   PLoS One

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

(2019) Hui Li et al.   GASTROENTEROLOGY

A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases and improves cancer immunity in preclinical lung cancer models

(2019) Qianwen Zhang et al.   CLINICAL CANCER RESEARCH

C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function

(2019) Yong Wang et al.   CIRCULATION

Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma

(2019) Rui-Yan Wu et al.   CLINICAL CANCER RESEARCH

Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy

(2019) Mauro Di Pilato et al.   NATURE

Hepatocellular Carcinoma

(2019) Augusto Villanueva   NEW ENGLAND JOURNAL OF MEDICINE

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Signaling and Function of Interleukin-2 in T Lymphocytes

(2018) Sarah H. Ross et al.   Annual Review of Immunology

Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma

(2018) Chun Jye Lim et al.   GUT

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model

(2018) Takayuki Kimura et al.   CANCER SCIENCE

Hippo Kinases Mst1 and Mst2 Sense and Amplify IL-2R-STAT5 Signaling in Regulatory T Cells to Establish Stable Regulatory Activity

(2018) Hao Shi et al.   IMMUNITY

Immune oncology in hepatocellular carcinoma—hype and hope

(2017) Marcus-Alexander Wörns et al.   LANCET

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Hepatocellular carcinoma

(2016) Josep M. Llovet et al.   Nature Reviews Disease Primers

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

(2015) A. Ribas   Cancer Discovery

Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice

(2012) Leonhard Stross et al.   HEPATOLOGY

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma

(2009) Jaw-Ching Wu et al.   JOURNAL OF HEPATOLOGY